Core One Labs Inc
CNSX:COOL
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
C
|
Core One Labs Inc
CNSX:COOL
|
6.8m CAD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Core One Labs Inc
Glance View
Core One Labs, Inc. is a biotechnology company, which engages in the manufacture of cannabis-infused strips. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-08-17. The firm is focused on advancing psychedelic medicines to market through delivery systems and psychedelic assisted psychotherapy and active pharmaceutical ingredients (API) grade psilocybin manufacturing. Core One has developed its technology, thin film oral strip, which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining bioavailability. The firm also intends to develop and apply the technology to psychedelic compounds, such as psilocybin. Core One produce current Good Manufacturing Practice (cGMP) API grade psilocybin for use by pharmaceutical companies, API manufacturers and organizations conducting clinical trials, providing access to organizations. Core One also holds an interest in medical clinics, which maintain a combined database of approximately 275,000 patients.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Core One Labs Inc is 27.4%, which is above its 3-year median of 21.1%.
Over the last 4 months, Core One Labs Inc’s Gross Margin has increased from 14.7% to 27.4%. During this period, it reached a low of 14.7% on Sep 30, 2023 and a high of 27.4% on Jan 31, 2024.
